Wall Street analysts project Kenvue to report Q2 2026 revenue of $3.97 billion and adjusted EPS of $0.32, with the current stock price of $19.24 sitting just below the average analyst target of $19.58.
Investors are primarily focused on the recovery of the Skin Health and Beauty segment, where analyst estimates target $1.1 billion in revenue for the quarter.
While Kenvue has a track record of earnings beats, sentiment remains cautious following soft results from sector peers and uncertainty regarding the pending Kimberly-Clark transaction. Success will likely depend on whether "Our Vue Forward" productivity initiatives can defend margins against volume pressures and fading pricing power across global markets.